Immunovant (IMVT) said Monday it appointed director Eric Venker as chief executive, succeeding Pete Salzmann, who has retired.
The company also named Tiago Girao as chief financial officer, succeeding Renee Barnett, who has stepped down from the role. Girao previously served as CFO of Telavant.
Immunovant said the changes are part of a "strategic realignment" under which Roivant Sciences (ROIV) will lead all investor relations activity of the company.
The company said it is expanding the development of IMVT-1402 into two new indications, namely Sjogren's Disease and Cutaneous Lupus Erythematosus.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。